NCT04421911

Brief Summary

Primary objective:

  • To assess therapeutic efficacy of the Ketoprofen compared with Diclofenac based on the assessment of primary endpoint : Mean change in walking arthritis pain intensity score Secondary objectives:
  • To assess therapeutic efficacy of the Ketoprofen compared with Diclofenac based on the assessment of secondary endpoints.
  • To assess safety and tolerability of the Ketoprofen compared with Diclofenac based on the nature and frequency of adverse events in treatment groups

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
236

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Mar 2020

Shorter than P25 for phase_3

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 20, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 2, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 9, 2020

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2020

Completed
Last Updated

January 20, 2021

Status Verified

January 1, 2021

Enrollment Period

6 months

First QC Date

June 2, 2020

Last Update Submit

January 19, 2021

Conditions

Keywords

ketoprofendiclofenacosteoarthritis

Outcome Measures

Primary Outcomes (1)

  • Mean change in walking arthritis pain intensity score

    Pain will be assessed by a horizontal 100 mm Visual Analogue Scale (VAS)

    3 weeks

Secondary Outcomes (4)

  • Mean change in spontaneous arthritis pain intensity score

    3 weeks

  • Knee injury and Osteoarthritis Outcome Score (KOOS)

    3 weeks

  • Global Impression of Improvement (PGI-I)

    3 weeks

  • Adverse events

    3 weeks

Study Arms (2)

ketoprofen

EXPERIMENTAL
Drug: Ketoprofen topical

Diclofenac

ACTIVE COMPARATOR
Drug: Diclofenac Topical

Interventions

Ketoprofen topical for 21days

ketoprofen

Diclofenac topical for 21days

Diclofenac

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 40-75 years
  • Compliance to ACR diagnostic criteria of OA of the knee
  • Patients with Kellgren-Lawrence grade 1-3
  • Index knee pain should be ≥40 mm on VAS (100mm) scale

You may not qualify if:

  • Intolerance or allergic reactions to the study therapy
  • Usage of NSAIDs within 3 days
  • Open skin lesions or dermatological conditions at the site of plaster application
  • Surgery or major trauma of the index knee within the previous 12 months
  • Pregnant or breast-feeding women
  • Alcohol addiction, drug addiction or drug abuse in the past

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Maksimum Zdorovya

Kemerovo, Russia

Location

City Clinical Hospital #1 n.a. Pirogova

Moscow, Russia

Location

Rostov State Medical University

Rostov-on-Don, Russia

Location

Ryazan State Medical University n.a. I.P.Pavlov

Ryazan, Russia

Location

Saratov State Medical University n.a. V.I.Razumovsky

Saratov, Russia

Location

Private Healthcare Institution Smolensk Russian Railway Clinical Hospital

Smolensk, Russia

Location

Ulyanovsk Regional Clinical Hospital

Ulyanovsk, Russia

Location

Regional Clinical Hospital

Vladimir, Russia

Location

Clinical Emergency Hospital n.a. N.V.Soloviev

Yaroslavl, Russia

Location

MeSH Terms

Conditions

Osteoarthritis

Interventions

KetoprofenDiclofenac

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

PhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsPhenylacetates

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 2, 2020

First Posted

June 9, 2020

Study Start

March 20, 2020

Primary Completion

September 1, 2020

Study Completion

September 1, 2020

Last Updated

January 20, 2021

Record last verified: 2021-01

Data Sharing

IPD Sharing
Will not share

Locations